the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
Published 2 years ago • 89 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
1:47
real-world safety and efficacy of talquetamab for the treatment of r/r myeloma
-
2:15
safety and efficacy of astx727 in patients with cmml from phase ii and phase iii ascertain studies
-
2:25
the safety & efficacy of copanlisib nivolumab in patients with rt and tnhl: a chemo-free approach
-
1:34
long-term surveillance for cardiac toxicities in patients with hl treated with chemotherapy
-
1:51
the safety and efficacy of retreatment with venetoclax plus rituximab in r/r cll
-
1:12
the safety and efficacy of mb-106 for the treatment of waldenström’s macroglobulinemia
-
2:53
long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials
-
3:36
the long-term outcomes of consolidative allosct for bpdcn
-
1:53
animation heal technology
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
0:43
elm-2: qol and orr outcomes of odronextamab treatment for r/r fl
-
2:57
linker-mm1: promising safety and efficacy of linvoseltamab in r/r multiple myeloma
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
3:01
updates from the bruin study – long-term safety of pirtobrutinib in r/r mcl
-
1:35
update on phase i study of plamotamab in r/r nhl
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:43
factors predicting durable remission after ifn therapy discontinuation in mpn patients
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
3:17
estimating transfusion-related medical costs & time burden in patients with mf in simplify-1
-
1:50
real-world outcomes of teclistamab treatment in r/r multiple myeloma